Skip to Content

Vedolizumab and Ustekinumab as Treatment for Patients with Ulcerative Colitis

In this MEDtalk, Thea Wiken elaborates on her study presented at ECCO 2024, comparing the effect of vedolizumab and ustekinumab in patients with ulcerative colitis who previously have been treated with anti-TNF-alpha inhibitors. The results show increased clinical remission in both groups, but only increased biochemical remission in patients treated with ustekinumab. The study also suggests that therapeutic drug management can have potential benefits in the treatment of ulcerative colitis patients.

Thea Wiken

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top